drugset / Trial / NCT01720264
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
Phase 2
Completed
15 enrolled
Sherif S. Farag
National Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).
Timeline
- Start
- 2012-11-02
- Primary completion
- 2016-08-27
- Completion
- 2017-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sitagliptin | Small molecule | — | Oral |